Factor VIII delivered by haematopoietic stem cell-derived B cells corrects the phenotype of haemophilia A mice

Ali Ramezani; Lynnsey A. Zweier-Renn; Robert G. Hawley

doi:10.1160/TH10-11-0725

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2011; 105(04): 676-687
DOI: 10.1160/TH10-11-0725

Animal Models

Schattauer GmbH

Factor VIII delivered by haematopoietic stem cell-derived B cells corrects the phenotype of haemophilia A mice

Authors

Ali Ramezani

¹Department of Anatomy and Regenerative Biology, The George Washington University, Washington, District of Columbia, USA
Lynnsey A. Zweier-Renn

¹Department of Anatomy and Regenerative Biology, The George Washington University, Washington, District of Columbia, USA

²Graduate Program in Biochemistry and Molecular Genetics, The George Washington University, Washington, District of Columbia, USA
Robert G. Hawley

¹Department of Anatomy and Regenerative Biology, The George Washington University, Washington, District of Columbia, USA

²Graduate Program in Biochemistry and Molecular Genetics, The George Washington University, Washington, District of Columbia, USA

Abstract

Summary

The main impediments to clinical application of haematopoietic stem cell (HSC) gene therapy for treatment of haemophilia A are the bone marrow transplant-related risks and the potential for insertional muta-genesis caused by retroviral vectors. To circumvent these limitations, we have adapted a non-myeloablative conditioning regimen and directed factor VIII (FVIII) protein synthesis to B lineage cells using an insulated lentiviral vector containing an immunoglobulin heavy chain enhancer-promoter. Transplantation of lentiviral vector-modified HSCs resulted in therapeutic levels of FVIII in the circulation of all transplanted mice for the duration of the study (six months). Immunostaining of spleen cells showed that the majority of FVIII was synthesised by B220⁺ B cells and CD138⁺ plasma cells. Subsequent challenge with recombinant FVIII elicited at most a minor anti-FVIII antibody response, demonstrating in-duction of immune hyporesponsiveness. All transplant recipients exhibited clot formation and survived tail clipping, indicating correction of their haemophilic phenotype. Therapeutic levels of FVIII could be transferred to secondary recipients by bone marrow transplantation, confirming gene transfer into long-term repopulating HSCs. Moreover, short-term therapeutic FVIII levels could also be achieved in secondary recipients by adoptive transfer of HSC-derived splenic B cells. Our findings support pursuit of B cell-directed protein delivery as a potential clinical approach to treat haemophilia A and other disorders correctable by systemically distributed proteins.

Keywords

Haemophilia A - animal models - haematopoietic stem cell gene therapy - B cell-targeted transgene expression - bioengineered factor VIII

Full Text

References

References
1 Hoyer LW, Hemophilia A. N Engl J Med. 1994 330. 38-47.
2 Ofosu FA, Freedman J, Semple JW. Plasma-derived biological medicines used to promote haemostasis. Thromb Haemost 2008; 99: 851-862.
3 Pipe SW. Recombinant clotting factors. Thromb Haemost 2008; 99: 840-850.
4 Coppola A, Di Minno MN, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol 2010; 150: 515-528.
5 Saenko EL, Ananyeva NM, Moayeri M. et al. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A. Curr Gene Ther 2003; 3: 27-41.
6 Doering CB, Spencer HT. Advancements in gene transfer-based therapy for hemophilia A. Expert Rev Hematol 2009; 2: 673-683.
7 Petrus I, Chuah M, Vandendriessche T. Gene therapy strategies for hemophilia: benefits versus risks. J Gene Med 2010; 12: 797-809.
8 Ramezani A, Hawley TS, Hawley RG. Performance- and safety-enhanced lentiviral vectors containing the human interferon-β scaffold attachment region and the chicken β-globin insulator. Blood 2003; 101: 4717-4724.
9 Ramezani A, Hawley TS, Hawley RG. Reducing the genotoxic potential of retroviral vectors. Methods Mol Biol 2008; 434: 183-203.
10 Ramezani A, Hawley TS, Hawley RG. Combinatorial incorporation of enhancer blocking components of the chicken β-globin 5‘HS4 and human T-cell receptor α/θ BEAD-1 insulators in self-inactivating retroviral vectors reduces their genotoxic potential. Stem Cells 2008; 26: 3257-3266.
11 Ramezani A, Hawley RG. Correction of murine hemophilia A following nonmyeloablative transplantation of hematopoietic stem cells engineered to encode an enhanced human factor VIII variant using a safety-augmented retroviral vector. Blood 2009; 114: 526-534.
12 Miao HZ, Sirachainan N, Palmer L. et al. Bioengineering of coagulation factor VIII for improved secretion. Blood 2004; 103: 3412-3419.
13 Parker ET, Healey JF, Barrow RT. et al. Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope. Blood 2004; 104: 704-710.
14 Montini E, Cesana D, Schmidt M. et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009; 119: 964-975.
15 Modlich U, Navarro S, Zychlinski D. et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 2009; 17: 1919-1928.
16 Brewer JW, Hendershot LM. Building an antibody factory: a job for the unfolded protein response. Nat Immunol 2005; 6: 23-29.
17 Klingemann HG. Mini-transplants turning micro: how low can we go?. J Hematother Stem Cell Res 2002; 11: 859-862.
18 Lei TC, Scott DW. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood 2005; 105: 4865-4870.
19 Scott DW. Gene therapy for immunological tolerance: using ‘transgenic’ B cells to treat inhibitor formation. Haemophilia 2010; 16: 89-94.
20 Dorner AJ, Bole DG, Kaufman RJ. The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins. J Cell Biol 1987; 105: 2665-74.
21 Lee YK, Brewer JW, Hellman R. et al. BiP and immunoglobulin light chain cooperate to control the folding of heavy chain and ensure the fidelity of immunoglobulin assembly. Mol Biol Cell 1999; 10: 2209-2219.
22 Zychlinski D, Schambach A, Modlich U. et al. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 2008; 16: 718-725.
23 Chang AH, Stephan MT, Sadelain M. Stem cell-derived erythroid cells mediate long-term systemic protein delivery. Nat Biotechnol 2006; 24: 1017-1021.
24 Ohmori T, Mimuro J, Takano K. et al. Efficient expression of a transgene in platelets using simian immunodeficiency virus-based vector harboring glycoprotein Ibalpha promoter: in vivo model for platelet-targeting gene therapy. FASEB J 2006; 20: 1522-1524.
25 Shi Q, Wilcox DA, Fahs SA. et al. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. J Thromb Haemost 2007; 5: 352-361.
26 Zhang G, Shi Q, Fahs SA. et al. Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice. Blood 2010; 116: 1235-1243.
27 Ochi A, Hawley RG, Hawley T. et al. Functional immunoglobulin M production after transfection of cloned immunoglobulin heavy and light chain genes into lymphoid cells. Proc Natl Acad Sci USA 1983; 80: 6351-6355.
28 Hawley RG, Covarrubias L, Hawley T. et al. Handicapped retroviral vectors efficiently transduce foreign genes into hematopoietic stem cells. Proc Natl Acad Sci USA 1987; 84: 2406-2410.
29 Oancea AE, Berru M, Shulman MJ. Expression of the (recombinant) endogenous immunoglobulin heavy-chain locus requires the intronic matrix attachment regions. Mol Cell Biol 1997; 17: 2658-2668.
30 Owens BM, Hawley TS, Spain LM. et al. TLX1/HOX11-mediated disruption of primary thymocyte differentiation prior to the CD4⁺CD8⁺ double-positive stage. Br J Haematol 2006; 132: 216-229.
31 Bi L, Lawler AM, Antonarakis SE. et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119-121.
32 Rawle FE, Shi CX, Brown B. et al. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains. J Gene Med 2004; 6: 1358-1368.
33 Ramezani A, Hawley TS, Hawley RG. Lentiviral vectors for enhanced gene expression in human hematopoietic cells. Mol Ther 2000; 2: 458-469.
34 Ramezani A, Hawley RG. Generation of HIV-1-based lentiviral vector particles. In: Current Protocols in Molecular Biology. New Jersey: John Wiley & Sons, Inc.; 2002. pp. 16.22.1-16.22.15.
35 Ide LM, Gangadharan B, Chiang KY. et al. Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens. Blood 2007; 110: 2855-2863.
36 Moayeri M, Ramezani A, Morgan RA. et al. Sustained phenotypic correction of hemophilia A mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells. Mol Ther 2004; 10: 892-902.
37 Manz RA, Lohning M, Cassese G. et al. Survival of long-lived plasma cells is independent of antigen. Int Immunol 1998; 10: 1703-1711.
38 Neubert K, Meister S, Moser K. et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748-755.
39 Moayeri M, Hawley TS, Hawley RG. Correction of murine hemophilia A by hematopoietic stem cell gene therapy. Mol Ther 2005; 12: 1034-1042.
40 Cavazzana-Calvo M, Payen E, Negre O. et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010; 467: 318-322.
41 Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984; 307: 168-170.
42 Bagley J, Bracy JL, Tian C. et al. Establishing immunological tolerance through the induction of molecular chimerism. Front Biosci 2002; 7: d1331-d1337.
43 Fehr T, Sykes M. Clinical experience with mixed chimerism to induce transplantation tolerance. Transpl Int 2008; 21: 1118-1135.
44 Qadura M, Othman M, Waters B. et al. Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells. J Thromb Haemost 2008; 6: 2095-2104.
45 Ragni MV, Wu W, Liang X. et al. Factor VIII-pulsed dendritic cells reduce anti-factor VIII antibody formation in the hemophilia A mouse model. Exp Hematol 2009; 37: 744-754.
46 de Boer-van den Berg MA, Uitendaal MP, Vermeer C. Direct measurement of vitamin K-dependent enzymes in various isolated and cultured tumor and non-tumor cells. Mol Cell Biochem 1987; 75: 71-76.
47 Ward NJ, Buckley SM, Waddington SN. et al. Codon optimisation of human factor VIII cDNAs leads to high level expression. Blood 2011; 117: 798-807.
48 Takacs K, Du RC, Nabarro S. et al. The regulated long-term delivery of therapeutic proteins by using antigen-specific B lymphocytes. Proc Natl Acad Sci USA 2004; 101: 16298-16303.
49 Kwakkenbos MJ, Diehl SA, Yasuda E. et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med 2010; 16: 123-128.
50 Tey SK, Dotti G, Rooney CM. et al. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 913-924.